Glenn  Coleman net worth and biography

Glenn Coleman Biography and Net Worth

Corporate Executive Vice President & Chief Financial Officer Management of Charles River Laboratories International

Glenn Coleman joined Charles River Laboratories in April of 2026 as Corporate Executive Vice President & Chief Financial Officer. In this role, Mr. Coleman leads the Company’s global Finance organization and oversees the Accounting, Tax, Treasury, Investor Relations, Internal Audit, Risk Management, Global Facilities and Real Estate, and Global Procurement functions, as well as works closely with operational finance teams across the global businesses.

Prior to joining Charles River, he served as Chief Financial Officer and Chief Administrative Officer of Premier, Inc. Earlier in his career, Mr. Coleman served as Executive Vice President and Chief Financial Officer at DENTSPLY from 2022 to 2024. Prior to DENTSPLY, he held operational and financial leadership positions at Integra Life Sciences from 2014 to 2022, including as Executive Vice President and Chief Operating Officer from 2019 to 2022, and previously as Chief Financial Officer and Corporate Vice President, International. Prior to Integra, Mr. Coleman spent 25 years in financial management positions with leading global manufacturing and telecommunications businesses, including Curtiss-Wright Corporation and Alcatel-Lucent, and began his career at PricewaterhouseCoopers LLP.

Mr. Coleman holds a Bachelor of Science degree in Business Administration from Montclair State University and is a Certified Public Accountant.

What is Glenn Coleman's net worth?

The estimated net worth of Glenn Coleman is at least $8.06 million as of September 30th, 2026. Mr. Coleman owns 27,762 shares of Charles River Laboratories International stock worth more than $8,059,808 as of October 4th. This net worth estimate does not reflect any other assets that Mr. Coleman may own. Learn More about Glenn Coleman's net worth.

How do I contact Glenn Coleman?

The corporate mailing address for Mr. Coleman and other Charles River Laboratories International executives is 251 Ballardvale ST, Wilmington, MA, 01887. Charles River Laboratories International can also be reached via phone at (781) 222-6000 and via email at [email protected]. Learn More on Glenn Coleman's contact information.

Has Glenn Coleman been buying or selling shares of Charles River Laboratories International?

Glenn Coleman has not been actively trading shares of Charles River Laboratories International during the last ninety days. Most recently, on Wednesday, September 30th, Glenn Coleman bought 10 shares of Charles River Laboratories International stock. The stock was acquired at an average cost of $297.43 per share, with a total value of $2,974.30. Following the completion of the transaction, the chief financial officer now directly owns 27,762 shares of the company's stock, valued at $8,257,251.66. Learn More on Glenn Coleman's trading history.

Who are Charles River Laboratories International's active insiders?

Charles River Laboratories International's insider roster includes William Barbo (VP), Robert Bertolini (Director), Stephen Chubb (Director), Glenn Coleman (Corporate Executive Vice President & Chief Financial Officer Management), Victoria Creamer (EVP), James Foster (CEO), Birgit Girshick (VP), Michael Knell (CAO), Deborah Kochevar (Director), Joseph LaPlume (EVP), George Massaro (Director), Shannon Parisotto (EVP), David Smith (CFO), and Richard Wallman (Director). Learn More on Charles River Laboratories International's active insiders.

Are insiders buying or selling shares of Charles River Laboratories International?

During the last year, Charles River Laboratories International insiders bought shares 1 times. They purchased a total of 10 shares worth more than $2,974.30. During the last year, insiders at the medical research company sold shares 10 times. They sold a total of 165,990 shares worth more than $42,606,388.18. The most recent insider tranaction occured on September, 30th when CFO Glenn Coleman bought 10 shares worth more than $2,974.30. Insiders at Charles River Laboratories International own 1.3% of the company. Learn More about insider trades at Charles River Laboratories International.

Information on this page was last updated on 9/30/2026.

Glenn Coleman Insider Trading History at Charles River Laboratories International

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/30/2026Buy10$297.43$2,974.3027,762View SEC Filing Icon  
See Full Table

Glenn Coleman Buying and Selling Activity at Charles River Laboratories International

This chart shows Glenn Coleman's buying and selling at Charles River Laboratories International by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Charles River Laboratories International Company Overview

Charles River Laboratories International logo
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More

Today's Range

Now: $290.32
Low: $285.75
High: $290.61

50 Day Range

MA: $277.46
Low: $224.50
High: $298.76

2 Week Range

Now: $290.32
Low: $146.20
High: $303.30

Volume

443,549 shs

Average Volume

938,162 shs

Market Capitalization

$13.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4